SEC asks Abbvie to conduct Phase III study on subcutaneous drug for Parkinson's disease: Our Bureau, New Delhi Friday, July 3, 2026, 08:00 Hrs [IST] A Subject Expert Committee (SE ...

Dopa-decarboxylase inhibitor + dopamine precursor. ≥18yrs: Do not crush or chew. Patients not receiving levodopa: initially one Sinemet CR 50–200 tab twice daily, at intervals of at least 6 hrs.

Credit: Thinkstock. The NDA is supported by data from the phase 3 RISE-PD trial. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IPX203 for the treatment of ...

Plastic waste has long been viewed as one of the world's most persistent environmental challenges. Yet researchers have now ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for multiple daily tablets. Scientists from the ...